Introduction & Objective: Ethnic minorities and older adults, who are disproportionately affected by T2D, are underrepresented in studies. This retrospective study assessed whether the fixed-ratio combination iGlarLixi improved outcomes vs complex insulin therapies in these populations.
Methods: Medicare claims data were used from African American, Asian, and Hispanic beneficiaries with T2D aged ≥65 years receiving basal insulin who newly initiated iGlarLixi, BB, or premixed insulin from Jan 1, 2019-Dec 31, 2021. Groups were propensity score matched (PSM) at baseline and followed for up to 12 months. The primary endpoint was treatment persistence. Secondary endpoints included treatment adherence and hypoglycemia event rates.
Results: PSM generated 1162 participants/group for iGlarLixi vs BB and 1160 vs premix. For iGlarLixi, persistence was statistically significantly higher, and adherence was numerically higher than BB or premixed insulin in the overall cohort. Hypoglycemia event rates were numerically lower for iGlarLixi vs BB or premixed insulin in the overall cohort. Similar findings were observed in African-American, Asian, and Hispanic groups (Table).
Conclusion: In minority populations with Medicare, iGlarLixi led to higher treatment persistence, numerically higher adherence, and lower hypoglycemia event rates compared to BB or premixed insulin.
G. Umpierrez: Research Support; Abbott, Bayer Inc., Dexcom, Inc., AstraZeneca. Advisory Panel; Dexcom, Inc. J. Gill: Employee; Sanofi-Aventis U.S. D. Hood: Employee; Pfizer Inc. X. Li: Employee; Sanofi. A. Núñez: None.
Sanofi US
